Programs offered by pharmaceutical companies for hepatitis C treatment

The pharmaceutical companies that make hepatitis C medications have programs to help people access and complete treatment.

These programs have phone support for people on treatment, and part of this support is helping people to access the funding necessary to cover treatment costs. These programs can inform patients about local, provincial, and federal government programs for accessing treatment and can help the patient find out ways to maximize any public funding or private medical insurance (including the appeals process, if the patient also has a supportive doctor).

If a person is eligible, some programs can help cover the insurance company co-pay fee, provincial or territorial plan's deductible, and a number of other expenses, depending on a person's specific situation.

AbbVie has the AbbVie Care Program for people taking Maviret (glecaprevir and pibrentasvir). Gilead Sciences has the Momentum HCV Support Program for people taking Epclusa (sofosbuvir and velpatasvir), Harvoni (sofosbuvir and ledipasvir), Sovaldi (sofosbuvir) or Vosevi (sofosbuvir, velpatasvir and voxilaprevir). Merck has the Merck Care Hepatitis Program for people taking Zepatier (elbasvir and grazoprevir).